Hydrogels for localized liver cancer chemotherapy: a possible strategy for improved and safe treatment of liver cancer

This article was originally published here

Deliver. 2022 Dec;29(1):1457-1476. doi: 10.1080/10717544.2022.2070299.


Systemic medicine has always been preferred for the treatment of the majority of pathological conditions, especially liver cancer. Indeed, this mode of treatment is associated with adverse effects, toxicity, off-target accumulation and rapid hepatic and renal clearance. Many efforts have been made to design systemic therapeutic carriers to improve retention while decreasing side effects and clearance. After systemic medication, local administration of therapeutic agents allows higher “effective” doses with fewer side effects, renal accumulation and clearance. Hydrogels are highly biocompatible and can be used for both imaging and therapy. The hydrogel-based drug delivery approach has fewer side effects than traditional chemotherapy and can deliver drugs to tumors for longer. The chemical and physical flexibility of hydrogels can be used to achieve disease-induced results. on the spot accumulation as well as subsequent drug release and programmed degradation by the hydrogel. Additionally, they may act as a biocompatible depot for localized chemotherapy when stimuli-responsive carriers are administered. Here, we summarize the design strategies of various hydrogels used for localized liver cancer chemotherapy and their routes of administration, as well as recent research on smart hydrogels.

PMID:35532174 | DO I:10.1080/10717544.2022.2070299

Comments are closed.